The first group is patients with tumours harbouring the KRAS exon 2 G13D mutation, who in retrospective series (with small numbers only) appear to respond to EGFR-I (in trials before KRAS selection became an eligibility criteria), but are currently precluded from accessing such treatment. Here, KRAS is linked to neoplasm.